Atossa Therapeutics, Inc. (BMV:ATOS)

Market Cap	2.59B
Revenue (ttm)	n/a
Net Income (ttm)	-541.57M
Shares Out	n/a
EPS (ttm)	-4.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66
Average Volume	3,235
Open	21.50
Previous Close	20.48
Day's Range	21.50 - 21.50
52-Week Range	13.00 - 31.00
Beta	n/a
RSI	67.10
Earnings Date	Nov 12, 2025

About Atossa Therapeutics

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Thera...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 15
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: ATOS

Financial Performance

Financial numbers in USD